Screening for the Prevalence of EGFR and Alk Mutations in Lung Adenocarcinoma Patients in the Levant Area, a Prospective Analysis

The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC)

“…In the current study, deletion in exon 19 was the most frequent type of EGFR mutations (65.8%) followed by L858R (26.3%) of all mutations, this is similar to studies in the East Asian countries (Liam et al, 2013;Shi et al, 2014;Lee et al, 2015;Shi et al, 2015). And is comparable to the study published in 2017, that revealed a deletion in exon 19 represents 78.1%, followed by exon 21 mutation 21.9% of all mutations (Tfayli et al, 2017). In contrast, Berois et al, reports that the most common mutations are rare mutations and only 40% of all mutations is the mutations in exon 19 and exon 21 (Berois et al, 2017).…”

“…In the current study, the EGFR mutations were detected in 27.53% of NSCLC patients. Despite, the prevalence rate was higher than that reported in the Saudi population and Lebanese population (Al-Kuraya et al, 2006;Fakhruddin et al, 2014;Kattan et al, 2015;Naderi et al, 2015), and higher than the prevalence rate reported by Tfayli et al in 2017 published study (Tfayli et al, 2017), this finding was still consistent with EGFR mutations frequency in the Middle East region, that ranging from 2.9% to 28.7% (Errihani et al, 2013;Jazieh et al, 2015;Zaki et al, 2015;Benbrahim et al, 2018), and lower than Asian countries that reached 45.5% (Yatabe et al, 2015;Tfayli et al, 2019). However, a review of 19 European studies by Szumera-Cieckiewicz et al, reported frequencies from European countries between (2.6% and 39%) in Italy and Germany, respectively (Szumera-Cieckiewicz et al, 2013).…”

Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017

“…It was found that the frequency of EGFR mutated NSCLC patients is 25.4% of all cases, with the highest number in Najd (central region), followed by non-Saudis and the least number was found to be in the southern region, while no other available researches in Saudi Arabia are present at the moment to compare with. Nevertheless, in the Middle Eastern region the only study of lung cancer-specific of EGFR mutation to date involves the levant population, the EGFR mutation was founded in 15.6% of NSCLC patients, which is lower than ours [17]. Moreover, the international numbers revealed a great variation; a higher number found to be in China 38.4%, followed by the Uruguayan population 18.3%, Europe is 14.1%, and the Caucasians 5.4% [14][15][16].…”

“…Regionally, a study in Levant area including Jordan, Syria, Lebanon reported 15.6% [17], and 20% in Morocco [18]. Two studies have been conducted in Saudi Arabia, one of them was not suitable for statistical analysis due to the low number of cases [19].…”

Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer

“…Nevertheless, Mraihi et al, (2018) found a frequency of 44% in a cohort of Tunisian patients using mutation-specific immunohistochemistry, which was in line with our results. Studies conducted in Arab countries reported frequencies ranging from 8.5-12% for Lebanon (Fakhruddin et al, 2014;Naderi et al, 2015), 15,6% for the Levant region (Tfayli et al, 2017), and up to 28.7 for the Gulf region (Jazieh et al, 2015). In the Turkish population, a previous study by Unal et al, (2013) revealed EGFR mutation frequency of 42.6% in NSCLC patients from western Turkey, but in recent large-scale studies, Tezel et al, (2017) showed that the mutation rate in Turkish NSCLC patients was 16,7%.…”